Detailed Phase III results for a new long-term prophylactic treatment for hereditary angioedema (HAE) have been presented at the annual meeting of the American Academy of Allergy Asthma & Immunology (AAAAI).
Developed by Australian biotech company CSL Limited (ASX: CSL), garadacimab is an investigational first-in-class treatment which uniquely inhibits the plasma protein, FXIIa.
CSL, which hopes to offer the once-monthly subcutaneous treatment for attacks related to HAE, announced top-line results from the VANGUARD study in August 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze